Navigation Links
Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
Date:10/25/2007

- Data Support NDA Submission -

TAMPA, Fla., Oct. 25 /PRNewswire-FirstCall/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced positive preliminary results from its Phase III difluprednate (ST-601) program, which evaluated the steroid's potential to rapidly resolve inflammation in the eye following ocular surgery.

"We are very pleased with the data that demonstrate difluprednate's potential as a potent, well-tolerated steroid treatment for post-operative inflammation," said Dr. Roger Vogel, Sirion's Chief Medical Officer. "Based on these data, Sirion is moving forward with its plans to submit a New Drug Application to the FDA."

The Phase III program consisted of two multi-center, randomized, double- masked studies that compared the safety and efficacy of difluprednate 0.05% to placebo, dosed two (BID) or four (QID) times daily beginning 24 hours after surgery. The studies included 439 subjects who presented with Grade 2 (an inflammatory cell count greater than or equal to 10) or higher the day after surgery. Inflammation was measured by the number of cells in the anterior chamber of the eye with a Grade 0 equaling less than or equal to one cell. The primary efficacy endpoint measured the proportion of subjects whose inflammation reached Grade 0 at Day 8.

Both difluprednate dosing regimens were superior to placebo at the primary endpoint, reaching high statistical significance at Day 8 and maintaining superiority through both the treatment period (Day 15) and the tapering period (Day 29). At Day 15, 56% of subjects on the BID regimen reached Grade 0 compared to 16% in the control group (p<0.0001). Of the subjects on the QID regimen, 63% reached Grade 0 at Day 15. This was also statistically significant when compared to placebo, but not clinically different than the BID regimen. In addition, both difluprednate groups were statistically better than placebo in eliminati
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Sirion Therapeutics Announces Clinical Data to be Presented at the 2007 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 According ... by Composition of Material, Application (Healthcare, Homeland security, ... Product (Personal Instrument, Hand-Held Instruments, Fixed, and Installed ... to 2013 - 2020", published by MarketsandMarkets, the Scintillator Market ... 5.62% from 2014 to 2020, and reach $479.16 ...
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
(Date:7/13/2014)... ECS is being founded by ... of a special needs child, I have become keenly ... for contemporary special education resources and evidence-based instruction. Emerald ... and families in the Seattle metro area that are ... education. We welcome the opportunity to serve our community ...
(Date:7/13/2014)... MI (PRWEB) July 13, 2014 If Dr. ... program he has just launched at http://www.HealthYourself101.com will ... visceral obesity. , Power has set out to provide ... ill effects that’s actually – dare we say it? – ... program,” says Power, “aims to engage the remote learner – ...
(Date:7/13/2014)... 13, 2014 According to the Living ... is a comprehensive guide that features a series of ... KP (keratosis pilaris). This guide consists of 14 ... Keratosis Pilaris? ,     Chapter 2: What Cause KP? ... I Have KP? ,     Chapter 4: Keratosis Pilaris ...
(Date:7/12/2014)... 13, 2014 According to the new ... Systems, Airborne Systems, and Naval Systems) - Global Forecasts ... Security and Surveillance Radar market are estimated to be ... a CAGR of 5.97% to reach $8.61 billion by ... with 47 figures spread through 161 pages and in-depth ...
(Date:7/12/2014)... Recently, iFitDress.com, one of the world’s leading wedding dress suppliers, ... . What’s more, all these hot outfits are available at ... spokesman states, “We are proud to announce our new red ... shopping experience. In addition to the big discounts, low shipping ... not always mean bad quality. All the red evening gowns ...
Breaking Medicine News(10 mins):Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Discounted Red Evening Gown Announced by iFitDress.com 2
... ... CradlePoint MBR1200 Router makes instant Internet access simple for small or remote offices; CradlePoint ... ... 10, 2010 -- Sprint (NYSE: S) has certified CradlePoint’s MBR1200 Failsafe Gigabit N Router ...
... finds , MONDAY, May 10 (HealthDay News) -- Smoking tobacco ... and those most likely to indulge are privileged young men ... , Young adults in Montreal who use water pipes, or ... away from their parents and have a higher household income ...
... A study by researchers from the Georgetown ... (GUMC) identifies a potential new combination therapy to "rescue" ... cancers. The findings were published on May 15, ... Therapeutics . Fulvestrant is a common second-line therapy ...
... Flavour is literally the spice of life and for ... would be unthinkable. Yet just this aspect of everyday ... developing abnormal eating behaviours including changes in food preferences, ... evidence that these behaviours are linked to a loss ...
... learn, seem to help later on, study suggests, , ... fed directly from the breast in early infancy tend ... counterparts, new research suggests. , This kind of self-regulation ... has found that breast-feeding protects against obesity. , ...
... ... Price and Dr. Donald Hensrud of Mayo Clinic are scheduled as keynote speakers at ... Atlanta, Georgia. , ... Florham Park, NJ (PRWEB) May 10, 2010 -- DTC Perspectives, Inc ., the ...
Cached Medicine News:Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 2Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 3Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 4Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 5Health News:CradlePoint Router and Mobile Broadband Adapter Pair With Sprint 4G to Create Instant Offices, Business Continuity Solutions 6Health News:Hookahs an Unhealthy Hit Among Privileged Young Adults 2Health News:Hookahs an Unhealthy Hit Among Privileged Young Adults 3Health News:Researchers discover new way to 'rescue' treatment sensitivity of breast cancer cells 2Health News:Dementia takes away the meaning of flavors 2Health News:Breast-Fed Babies Know When to Say When 2Health News:Breast-Fed Babies Know When to Say When 3Health News:Dr. Kessler, Congressman Price & Mayo Clinic Headline Inaugural MDPA Conference 2Health News:Dr. Kessler, Congressman Price & Mayo Clinic Headline Inaugural MDPA Conference 3
Used for placement of choledochoscopes, cholangiography catheters and other instruments. Supplied sterile in peel-open packages. Intended for one-time use....
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
... Marker directly to the biopsy site helps ... performed. ,The MICROMARK® II Tissue Marker is ... for use with the MAMMOTOME Biopsy System. ... site after a biopsy with the MAMMOTOME ...
... A biopsy with the ... an effective, minimally invasive procedure ... patient management.,Using computer-generated images to ... more accurately pinpoint and map ...
Medicine Products: